Chimeric Antigen Receptors Targeting B-Cell Maturation Antigen
Patent No. EP3689383 (titled "Chimeric Antigen Receptors Targeting B-Cell Maturation Antigen") was filed by The United States OF America on Mar 15, 2013. The application was issued on Dec 31, 2025.
Patent Summary
A pharmaceutical composition comprising T-cells engineered to express a chimeric antigen receptor (CAR) that targets B-cell Maturation Antigen (BCMA) for the treatment of multiple myeloma. The CAR comprises an antigen recognition moiety directed against BCMA and a T-cell activation moiety that includes a transmembrane domain and an intracellular signaling domain. The composition is administered to patients with multiple myeloma to induce antigen-specific T-cell responses against BCMA-expressing cancer cells.
UPC Cases New
Latest UPC cases involving this patent.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3689383
- Application Number
- EP19216091A
- Filing Date
- Mar 15, 2013
- Status
- Granted And Under Opposition
- Nov 28, 2025
- Publication Date
- Dec 31, 2025
- External Links
- Slate, Register , Google Patents